Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity.
Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity.
复制标题
DOI:
10.1038/s41420-021-00602-0
复制
发表时间:
2021-09-15
影响因子:
7
通讯作者:
Pulinilkunnil T
中科院分区:
文献类型:
--
作者:
Biswas D;Slade L;Duffley L;Mueller N;Dao KT;Mercer A;Pakkiriswami S;El Hiani Y;Kienesberger PC;Pulinilkunnil T
Triple-negative breast cancers (TNBCs) are characterized by poor survival, prognosis, and gradual resistance to cytotoxic chemotherapeutics, like doxorubicin (DOX). The clinical utility of DOX is limited by its cardiotoxic and chemoresistant effects that manifest over time. To induce chemoresistance, TNBC rewires oncogenic gene expression and cell signaling pathways. Recent studies have demonstrated that reprogramming of branched-chain amino acids (BCAAs) metabolism facilitates tumor growth and survival. Branched-chain ketoacid dehydrogenase kinase (BCKDK), a regulatory kinase of the rate-limiting enzyme of the BCAA catabolic pathway, is reported to activate RAS/RAF/MEK/ERK signaling to promote tumor cell proliferation. However, it remains unexplored if BCKDK action remodels TNBC proliferation and survival per se and influences susceptibility to DOX-induced genotoxic stress. TNBC cells treated with DOX exhibited reduced BCKDK expression and intracellular BCKAs. Genetic and pharmacological inhibition of BCKDK in TNBC cell lines also showed a similar reduction in intracellular and secreted BCKAs. BCKDK silencing in TNBC cells downregulated mitochondrial metabolism genes, reduced electron complex protein expression, oxygen consumption, and ATP production. Transcriptome analysis of BCKDK silenced cells confirmed dysregulation of mitochondrial metabolic networks and upregulation of the apoptotic signaling pathway. Furthermore, BCKDK inhibition with concurrent DOX treatment exacerbated apoptosis, caspase activity, and loss of TNBC proliferation. Inhibition of BCKDK in TNBC also upregulated sestrin 2 and concurrently decreased mTORC1 signaling and protein synthesis. Overall, loss of BCKDK action in TNBC remodels BCAA flux, reduces protein translation triggering cell death, ATP insufficiency, and susceptibility to genotoxic stress. Proposed mechanism. A Doxorubicin (DOX) targets the BCAA catabolic pathway in TNBCs, by downregulating BCKDK and augmenting clearance of intracellular BCKAs. B Genetic or pharmacological (high BT2 concentration) inhibition of BCKDK results in increased cell death, decreased intracellular BCKAs, dysregulated mitochondrial function, ATP insufficiency, SESN2 activation, and inhibition of mTORC1 signaling and protein synthesis. C BCKDK inhibition (siRNA mediated or low-BT2 concentration) exacerbates DOX-induced cytotoxicity and caspase activity.
登录
查看更多内容
影响因子:
29
作者:
Pavlova NN;Thompson CB
通讯作者:
Thompson CB
DOI:
10.1016/j.bbagen.2017.02.019
发表时间:
2017-05-01
影响因子:
3
作者:
Dartier, Julie;Lemaitre, Elsa;Dumas, Jean-Francois
通讯作者:
Dumas, Jean-Francois
DOI:
10.1083/jcb.200208089
发表时间:
2003-01-06
期刊:
The Journal of cell biology
影响因子:
--
作者:
Ricci JE;Gottlieb RA;Green DR
通讯作者:
Green DR
影响因子:
8
作者:
Peng H;Wang Y;Luo W
通讯作者:
Luo W
DOI:
10.1016/j.biocel.2014.01.025
发表时间:
2014-05-01
影响因子:
4
作者:
Moreno-Sanchez, Rafael;Marin-Hernandez, Alvaro;Rodriguez-Enriquez, Sara
通讯作者:
Rodriguez-Enriquez, Sara